	US 12,351,607 B2
	Horn fly vaccine compositions and methods of making same
Kent R. Van Kampen, Payson, UT (US); and Serge Martinod, Groton, CT (US)
Assigned to GNT Pharmaceuticals, Inc., Louisville, KY (US)
Filed by TNG Pharmaceuticals, Inc., Louisville, KY (US)
Filed on Sep. 6, 2023, as Appl. No. 18/242,627.
Application 18/242,627 is a continuation of application No. 16/771,800, granted, now 11,780,894, previously published as PCT/US2018/065407, filed on Dec. 13, 2018.
Claims priority of provisional application 62/598,658, filed on Dec. 14, 2017.
Prior Publication US 2024/0141000 A1, May 2, 2024
Int. Cl. C07K 14/435 (2006.01); A61K 39/00 (2006.01)

CPC C07K 14/43577 (2013.01) [A61K 39/0003 (2013.01); A61K 39/00 (2013.01); A61K 2039/552 (2013.01); A61K 2039/575 (2013.01); C07K 2319/24 (2013.01); C07K 2319/40 (2013.01)]

9 Claims

1. A fusion protein comprising a. a truncated thrombostasin protein comprising a carboxy terminal deletion, wherein said truncated thrombostasin protein is selected from: SEQ ID NO: 13, SEQ ID NO: 14, and SEQ ID NO: 15, and combinations thereof; and

b. a fusion partner protein comprising a non-thrombostasin protein component.